Home » Topics » BioWorld Science

BioWorld Science
RSS

Zentalis begins phase I/II trial of DDR drug candidate ZN-c3

Dec. 23, 2019

Vaccitech Oncology collaborates with Cancer Research UK on phase I/IIa study of VTP-600 vaccine

Dec. 23, 2019

OP-1250 shrinks ER-positive breast tumors in xenograft models

Dec. 23, 2019

Novel mouse models of chronic sustained hypoxia and chronic intermittent hypoxia

Dec. 23, 2019

FDA approves Ervebo for prevention of Ebola virus disease

Dec. 20, 2019

Cullinan Oncology announces phase I/IIa trials of VK-2019 and CLN-081

Dec. 20, 2019

Axovant reports preliminary findings from expanded access treatment with AXO-AAV-GM1

Dec. 20, 2019

Bone Therapeutics submits CTA for pivotal study of JTA-004 for knee osteoarthritis

Dec. 20, 2019

Imeglimin completes pivotal phase III program for type 2 diabetes in Japan

Dec. 20, 2019

Roche describes new Toll-like receptor 7/8/9 antagonists

Dec. 20, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent
BioWorld Science
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...